Advantages and clinical application of militizumab targeting IL-23

Milikizumab (Mirikizumab) is a new type of humanized monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23) and shows unique advantages in the treatment of chronic immune diseases. IL-23 is a key cytokine in the inflammatory cascade and is related to a variety of autoimmune diseases, especially moderate to severe ulcerative colitis (UC) and psoriasis.

Milizumab can inhibit the activation of Th17 cells by specifically blocking the IL-23 signaling pathway, thereby reducing the release of pro-inflammatory cytokines and achieving a long-lasting anti-inflammatory effect. Compared with early antibody drugs targeting IL-12/23, such as ustekinumab, militizumab is more selective and only targets the p19 subunit, thereby avoiding affecting IL-12-related immune pathways and helping to retain normal immune defense functions against viruses and bacteria.

Clinically, militizumab is mainly used for the long-term control treatment of moderately to severely active ulcerative colitis. Its route of administration is intravenous or subcutaneous injection, and it is suitable for patients who are ineffective or intolerant to traditional immunosuppressants or TNF-α inhibitors. Studies have shown that militizumab is superior in inducing remission, maintaining mucosal healing and reducing intestinal symptoms, and some patients can achieve significant improvement within weeks. In addition, its targeting mechanism is relatively clear, drug resistance develops slowly, the incidence of adverse reactions is low, and it has good long-term compliance. Because militizumab does not suppress the entire immune system, its infection risk is controlled at a low level and is more friendly to patients with chronic diseases.

Overall, as an IL-23 target drugmilitizumab provides a more precise immune regulation pathway for the treatment of moderate to severe ulcerative colitis in terms of safety, targeting and clinical remission effect.

Reference materials:https://omvoh.lilly.com/